According to an exchange filing, the inspection was conducted from 28 July to 1 August 2025. The company reported that the inspection concluded with zero observations.

Torrent Pharmaceuticals is the flagship of the Torrent Group and ranks seventh in the Indian pharmaceutical market. It is among the top five players in key therapeutic areas such as cardiovascular, gastrointestinal, central nervous system, and cosmo-dermatology. With nearly 76% of its India business coming from chronic and sub-chronic therapies, Torrent remains a focused, specialty-driven player.

The pharma major reported a net profit of Rs 548 crore in Q1 FY25, marking a 20% year-on-year increase. Revenue for the quarter stood at Rs 3,178 crore, an 11% rise over Q1 FY25.

The scrip slipped 1.34% to Rs 3,624.85 on the BSE.